GEAP201614782A - - Google Patents

Info

Publication number
GEAP201614782A
GEAP201614782A GEAP2016014782A GEAP201614782A GE AP201614782 A GEAP201614782 A GE AP201614782A GE AP2016014782 A GEAP2016014782 A GE AP2016014782A GE AP201614782 A GEAP201614782 A GE AP201614782A
Authority
GE
Georgia
Application number
Other languages
English (en)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=54548063&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=GEAP201614782(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed filed Critical
Publication of GEAP201614782A publication Critical patent/GEAP201614782A/en
Publication of GEP20207178B publication Critical patent/GEP20207178B/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/007Pulmonary tract; Aromatherapy
    • A61K9/0073Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/194Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605Excipients; Inactive ingredients
    • A61K9/1617Organic compounds, e.g. phospholipids, fats
    • A61K9/1623Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/08Bronchodilators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
GEAP201614782A 2015-11-16 2016-11-14 Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic GEP20207178B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP15194661 2015-11-16
PCT/EP2016/077566 WO2017085007A1 (en) 2015-11-16 2016-11-14 A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic

Publications (2)

Publication Number Publication Date
GEAP201614782A true GEAP201614782A (https=) 2020-04-27
GEP20207178B GEP20207178B (en) 2020-11-10

Family

ID=54548063

Family Applications (2)

Application Number Title Priority Date Filing Date
GEAP202014782A GEAP202014782A (en) 2015-11-16 2016-11-14 Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic
GEAP201614782A GEP20207178B (en) 2015-11-16 2016-11-14 Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic

Family Applications Before (1)

Application Number Title Priority Date Filing Date
GEAP202014782A GEAP202014782A (en) 2015-11-16 2016-11-14 Process for preparing dry powder formulation comprising anticholinergic, corticosteroid and beta-adrenergic

Country Status (31)

Country Link
US (3) US10086003B2 (https=)
EP (2) EP3689379B1 (https=)
JP (1) JP6942126B2 (https=)
KR (1) KR20180082442A (https=)
CN (1) CN108348614B (https=)
AR (1) AR106687A1 (https=)
AU (1) AU2016357988B2 (https=)
CA (1) CA3005291C (https=)
CL (1) CL2018001297A1 (https=)
CO (1) CO2018005139A2 (https=)
DK (2) DK3377109T3 (https=)
EA (1) EA037346B1 (https=)
ES (2) ES2789365T3 (https=)
GE (2) GEAP202014782A (https=)
HR (2) HRP20200571T1 (https=)
HU (2) HUE056402T2 (https=)
IL (1) IL259327B (https=)
MA (1) MA52437A (https=)
MX (1) MX377113B (https=)
MY (1) MY198321A (https=)
PE (1) PE20181377A1 (https=)
PH (1) PH12018501023A1 (https=)
PL (2) PL3377109T3 (https=)
PT (2) PT3377109T (https=)
SA (1) SA518391574B1 (https=)
SG (2) SG11201804048WA (https=)
SI (2) SI3377109T1 (https=)
TW (1) TWI729025B (https=)
UA (1) UA125173C2 (https=)
WO (1) WO2017085007A1 (https=)
ZA (1) ZA201803167B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN110612095A (zh) * 2017-05-11 2019-12-24 奇斯药制品公司 制备包含抗胆碱能药、皮质类固醇和β-肾上腺素能药的干粉制剂的方法
CA3060020A1 (en) 2017-05-11 2018-11-15 Chiesi Farmaceutici S.P.A. A process for preparing a dry powder formulation comprising an anticholinergic, a corticosteroid and a beta-adrenergic
WO2019060595A1 (en) * 2017-09-20 2019-03-28 Teva Branded Pharmaceutical Products R&D, Inc. INHALABLE DRY POWDER MEDICINAL PRODUCT COMPRISING GLYCOPYRRONIUM
CN112823009A (zh) * 2019-08-28 2021-05-18 上海谷森医药有限公司 糠酸氟替卡松脂质体制剂及其制备方法
WO2021143785A1 (zh) * 2020-01-15 2021-07-22 四川海思科制药有限公司 一种含茚达特罗的吸入气雾剂药物组合物及其制备方法
CN111467498A (zh) * 2020-05-14 2020-07-31 王兆霖 药物组合物制剂
CN117064869A (zh) * 2023-09-27 2023-11-17 山东京卫制药有限公司 一种胶囊型吸入粉雾剂及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20011227A1 (es) 2000-04-17 2002-01-07 Chiesi Farma Spa Formulaciones farmaceuticas para inhaladores de polvo seco en la forma de aglomerados duros
GB0015043D0 (en) 2000-06-21 2000-08-09 Glaxo Group Ltd Medicament dispenser
EP1658872B2 (en) 2002-07-31 2019-08-21 CHIESI FARMACEUTICI S.p.A. Powder inhaler
JP2009514779A (ja) * 2003-07-11 2009-04-09 グラクソ グループ リミテッド 医薬製剤
GB0410399D0 (en) * 2004-05-10 2004-06-16 Arakis Ltd The treatment of respiratory disease
WO2011131663A1 (en) 2010-04-21 2011-10-27 Chiesi Farmaceutici S.P.A. "process for providing particles with reduced electrostatic charges"
US9393202B2 (en) 2013-04-26 2016-07-19 Chiesi Farmaceutici S.P.A Particle size reduction of an antimuscarinic compound
HUE053957T2 (hu) * 2013-07-11 2021-08-30 Chiesi Farm Spa Antikolinerg, kortikoszteroid és béta-adrenerg anyagot tartalmazó száraz porkészítmény inhalálással történõ beadásra

Also Published As

Publication number Publication date
JP6942126B2 (ja) 2021-09-29
AR106687A1 (es) 2018-02-07
CO2018005139A2 (es) 2018-08-10
US10959944B2 (en) 2021-03-30
EA037346B1 (ru) 2021-03-16
KR20180082442A (ko) 2018-07-18
MA52437A (fr) 2021-05-05
US20170136034A1 (en) 2017-05-18
NZ742473A (en) 2024-11-29
DK3377109T3 (da) 2020-04-20
MX2018005979A (es) 2018-08-29
EP3689379A1 (en) 2020-08-05
EA201890967A1 (ru) 2018-12-28
US20190021994A1 (en) 2019-01-24
PT3377109T (pt) 2020-05-13
US10086003B2 (en) 2018-10-02
CN108348614A (zh) 2018-07-31
PH12018501023B1 (en) 2018-12-17
CA3005291C (en) 2024-01-16
CN108348614B (zh) 2021-09-21
US20200360278A1 (en) 2020-11-19
HUE056402T2 (hu) 2022-02-28
CA3005291A1 (en) 2017-05-26
GEP20207178B (en) 2020-11-10
JP2018537453A (ja) 2018-12-20
DK3689379T3 (da) 2021-09-06
PE20181377A1 (es) 2018-09-05
IL259327B (en) 2020-11-30
HRP20211599T1 (hr) 2022-01-07
PT3689379T (pt) 2021-09-24
EP3377109B1 (en) 2020-03-04
BR112018009811A8 (pt) 2019-02-26
HRP20200571T1 (hr) 2020-07-10
SI3689379T1 (sl) 2021-11-30
HK1256859A1 (zh) 2019-10-04
TW201722403A (zh) 2017-07-01
HUE050343T2 (hu) 2020-11-30
ES2890409T3 (es) 2022-01-19
EP3377109A1 (en) 2018-09-26
GEAP202014782A (en) 2020-04-27
PH12018501023A1 (en) 2018-12-17
IL259327A (en) 2018-07-31
AU2016357988A1 (en) 2018-05-31
MY198321A (en) 2023-08-24
PL3377109T3 (pl) 2020-09-21
SI3377109T1 (sl) 2020-07-31
TWI729025B (zh) 2021-06-01
AU2016357988B2 (en) 2021-12-16
UA125173C2 (uk) 2022-01-26
BR112018009811A2 (pt) 2018-11-13
CL2018001297A1 (es) 2018-08-10
WO2017085007A1 (en) 2017-05-26
PL3689379T3 (pl) 2021-12-13
SG10201912090UA (en) 2020-02-27
EP3689379B1 (en) 2021-08-11
US10786451B2 (en) 2020-09-29
SA518391574B1 (ar) 2021-06-13
MX377113B (es) 2025-03-07
ZA201803167B (en) 2019-07-31
ES2789365T3 (es) 2020-10-26
SG11201804048WA (en) 2018-06-28

Similar Documents

Publication Publication Date Title
BR112016021638A2 (https=)
BR112017027386A2 (https=)
GEAP201614782A (https=)
BR112018004516A2 (https=)
BR0009349B1 (https=)
BR0009761B1 (https=)
CN303068595S (https=)
CN303066724S (https=)
CN303063474S (https=)
BR9811518B1 (https=)
BR9806716B1 (https=)
CN303070920S (https=)
CN303072223S (https=)
CN303074406S (https=)
BR0318565B1 (https=)
BR0106879B1 (https=)
BR0015643B1 (https=)
BR0009994B1 (https=)
BR0009942B1 (https=)
BR0008789B1 (https=)
BR0009757B1 (https=)
BR0009717B1 (https=)
BR0009649B1 (https=)
BR0009373B1 (https=)
BR0008158B1 (https=)